Truist lifts target for SI-BONE stock to USD 25.00

Published on 10/15/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 56.01 million. SI-BONE stock costs EUR 17.65 on October 15, 2026, up 2.04 percent on Nasdaq versus October 14.

Analyst target and quarterly revenue

Truist raised its SI-BONE target to USD 25.00 from USD 23.00 on October 14, 2026.
SI-BONE revenue reached USD 56.01 million in the second quarter of 2026.
SI-BONE stock costs EUR 17.65 at Lang & Schwarz on October 15, 2026 at 6:46 p.m. CEST, plus 2.04 percent on Nasdaq versus October 14, 2026.
SI-BONE is estimated to report third-quarter 2026 results on November 9, 2026.

SIBN, US8257041090, Illustration mit AI erstellt.

Truist raised its price target for SI-BONE (ISIN US8257041090) to USD 25.00 from USD 23.00 on October 14, 2026, according to Markets Insider. The new target stands 25.80 percent above SI-BONE's USD 19.87 Nasdaq price from October 15, 2026. The euro quotation was EUR 17.65 at Lang & Schwarz on October 15, 2026 at 6:46 p.m. CEST, while the Nasdaq move was plus 2.04 percent versus the October 14 close.

Revenue provides the second marker

SI-BONE reported USD 56.01 million in revenue for the second quarter of 2026, up from USD 52.59 million in the first quarter. Net loss attributable to common shareholders was USD 4.09 million, while diluted earnings per share were minus USD 0.09 for the quarter. The figures come from the company's investor-relations materials and standardized financial reporting, with the reporting period ending June 30, 2026.

Stock remains inside its yearly range

The Nasdaq price of USD 19.87 sits between the 52-week low of USD 11.48 and the 52-week high of USD 21.89 as of October 15, 2026. That places the stock 9.23 percent below its yearly high and 73.17 percent above its yearly low. The day's Nasdaq volume was 188,750 shares against an average volume of 544,125 shares.

Valuation and November date

SI-BONE had a market capitalization of USD 890.4 million and a trailing price-to-earnings ratio of minus 58.47 on October 15, 2026. The dividend yield was 0.00 percent. MarketBeat lists November 9, 2026 as the estimated date for the third-quarter 2026 report, after the market closes.

Comparison with peers

SI-BONE (Nasdaq, USD): plus 2.04 percent, P/E minus 58.47, market capitalization USD 890.4 million

Alphatec Holdings (Nasdaq, USD): plus 4.02 percent, P/E minus 15.08, market capitalization USD 1.7 billion

Orthofix Medical (Nasdaq, USD): plus 4.17 percent, P/E minus 6.27, market capitalization USD 389.5 million

Price and investor dates

SI-BONE's euro quotation at Lang & Schwarz stood at EUR 17.65 on October 15, 2026 at 6:46 p.m. CEST. The Nasdaq price of USD 19.87 remained below the USD 25.00 Truist target on the same date, while the next estimated reporting date is November 9, 2026.

The further course of trading is shown by the continuously updated real-time quote of SI-BONE stock.